anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an antibody molecule having specificity for the antigenic determinant of a human tumor necrosis factor α(TNFα), and to provide a curative use of the antibody molecule, and to provide a method for producing the same.  &lt;P&gt;SOLUTION: The antibody molecule contains at least one CDR(complementarity determining region) derived from a mouse monoclonal antibody having specificity for the antigenic determinant of a human TNFα. A CDR-grafted antibody wherein at least one of the CDRs is a hybrid CDR is also provided. Furthermore, DNA sequences encoding the chains of the antibody molecules, vectors, and transformed host cells are provided, respectively. Another version of the above antibody molecule covalent-bonded with a methoxypoly(ethylene glycol) residue is also provided. Besides, uses of these antibody molecules in the treatment of diseases mediated by TNFα are provided.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
PURPOSE:To provide a washing agent composition for bodies, having a refreshing use touch, little in the adsorption to skins, having good safety, exhibiting sufficient foamability, and capable of being well used also in hard water. CONSTITUTION:The washing agent composition for bodies is characterized by simultaneously using the salt of a fatty acid not containing a &lt;=12C fatty acid and an N-acyltaurine salt. The N-acyltaurine salt is suitably compounded in an amount of 0.1-30.0wt.%. When the salt of the fatty acid containing the &lt;=12C fatty acid is used, the N-acyltaurine salt and a polyoxyethylene hardened caster oil are simultaneously used. The N-acyltaurine salt and the polyoxyethylene hardened caster oil are suitably compounded in amounts of 0.1-30.0wt.% and 0.1-30.0wt.%, respectively, based on the fatty acid salt and in a compounding ratio of 4:1 to 1:1. The adsorbability of the washing agent composition to skins is lowered without damaging the refreshing use touch of the fatty acid salt, and the foamability can be improved.
PCT No. PCT/IB94/00166 Sec. 371 Date Dec. 14, 1995 Sec. 102(e) Date Dec. 14, 1995 PCT Filed Jun. 20, 1994 PCT Pub. No. WO95/00651 PCT Pub. Date Jan. 5, 1995The present invention relates to a polypeptide having the amino acid sequence SEQ ID NO:2 or an analogue or variant thereof having SCCE activity as defined in the present application, such as a polypeptide having a subsequence of the amino acid sequence SEQ ID NO:2. Furthermore, the present invention relates to nucleotide sequences encoding polypeptides having SCCE activity as well as to expression systems, expression vectors, plasmids and non-human organisms comprising said nucleotide sequences. Important aspects of the present invention relate to pharmaceutical, cosmetic and skin care compositions comprising a polypeptide having SCCE activity, and the use of a polypeptide having SCCE activity for the treatment or prophylaxis of various diseases such as acne, xeroderma or other hyperkeratotic conditions such as callosities and keratosis pilaris as well as the various ichthyoses, psoriasis and other inflammatory skin diseases such as eczemas. Moreover, the present invention relates to the use of a compound which has an inhibitory effect on the enzymatic activity of native SCCE for the manufacture of a pharmaceutical composition for treatment or prophylaxis of autoimmune pemphigus diseases or acantholytic diseases such as familiar pemphigus and Darier&#39;s disease.
PURPOSE:An external drug, obtained by incorporating a percutaneous absorption promoter containing an ether compound of a specific glycerol or polyglycerol with an alcohol in a base, and capable of remarkably increasing the percutaneous absorbability of a drug effect component. CONSTITUTION:A percutaneous absorption promoter containing an ether compound of glycerol or polyglycerol with an alcohol expressed by formula I or II(R1-R4 are H, 1-24C saturated or unsaturated straight chain or branched chain aliphatic hydrocarbon, etc.; n R4s may be the same or different except when all R1-R4 are H; n is an integer 0-60) as an active component is contained in a base to enhance the percutaneous absorbability of an external drug. The amount of the promoter to be added is preferably 0.01-5wt% based on the total amount of the external drug. In use thereof as a base, the amount of the promoter to be incorporated may be &gt;=10wt%. The promoter can be formulated in either one of hydrophilic and hydrophobic bases, and a drug effect component sparingly soluble in water can be dissolved in the hydrophilic base in a high concentration.
The present invention relates to a fusion protein SG-LDP-AE in strengthened genetic engineering, which is prepared by two technical lines: genetic engineering construction and molecule strengthening of the fusion protein. The fusion protein has strong effect on damaging tumor cells. The fusion protein can carry out specific combination with the tumor cells for expressing an epidermal growth factor receptor (EGFR) in vitro. An animal experiment shows that the fusion protein has obvious therapeutic effect on the transplanted liver cancer H22 of a mouse. When tolerable dose of the fusion protein is used, the inhibition ratio can reach to 95.8% (p&lt;0.001). The result shows the characteristics of miniaturization and high efficiency of targeted drugs. The present invention is expected to be a novel targeted drug used for clinical tumor treatment.
The invention belongs to the technical field of nerve repair, and discloses a novel intestinal tract supplement, a preparation method and application thereof, wherein the novel intestinal tract supplement consists of probiotics and xylo-oligosaccharides according to parts by mass. The probiotics include: bifidobacterium lactis and lactobacillus acidophilus. The novel intestinal supplement comprises 2.5X10  9  CFU/mL bifidobacterium lactate and Lactobacillus acidophilus, and 0.5g xylo-oligosaccharide. Preparing 70 lactobacillus acidophilus and xylo-oligosaccharide into freeze-dried powder to obtain the novel intestinal tract supplementAnd (5) filling. Use of a novel intestinal supplement for the manufacture of a medicament for the treatment or alleviation of a central nervous system disorder. The novel intestinal supplement provided by the invention can regulate intestinal metabolism and remodel intestinal flora by activating PPARs signal paths so as to reduce the neuroinflammatory response of Alzheimer&#39;s disease and achieve the effect of treating or relieving Alzheimer&#39;s disease.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a film preparation for the oral mucosa including a pH regulator for improving the absorption through the oral mucosa and eliminating the instability of a drug by effects of the pH regulator in the film preparation of the type through the oral mucosa by applying to the oral mucosa or dissolving in the oral cavity and absorbing the drug through the oral mucosa.  &lt;P&gt;SOLUTION: The film preparation for the oral mucosa is provided with a soluble drug layer containing the drug and disintegrating or soluble non-drug layers without containing the drug. The pH regulator for improving the absorption of the drug through the oral mucosa is contained in the non-drug layers without including the pH regulator in the drug layer. In particular, the drug is a compound of fentanyls. The pH regulator is such as sodium hydroxide, trisodium phosphate, anhydrous dibasic sodium phosphate, citric acid, etc.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
FIELD: medicine. ^ SUBSTANCE: strain of Bifidobacterium longum is separated from bowels content of healthy baby and is deposited in Government collection of microorganisms of normal microflora (GKNM) FSIS &#34;MNIIEM named after G.N. Gabrichevskiy Rospotrebnadzor &#34; under registration number 230. Strain multiplies in various nutrition mediua with accumulation of production biomass with high concentration of bifidobacteria. ^ EFFECT: Bifidobacterium longum strain has acid-forming activity, antagonistic activity with respect to pathogenic and opportunistic microorganisms, ferments milk, which makes it possible to apply it for obtaining bifidocontaining production. ^ 2 tbl, 5 ex
1. Technical Result Increase in treatment efficiency.         2. Essence For inhibiting of thrombus formation a fibrin-specific monoclonal antibody MH-1 or an antibody produced by cells of hybridome ATCC9739 or an antibody, which is connected with the same epitope that antibody MH-1 or a fragment or a derivative of one of the mentioned antibodies, which contain the binding domain of the appropriate antibody are introduced in a person&#39;s organism. The pharmaceutical composition comprises one of the mentioned antibodies or a fragment of antibody or a derivative and pharmaceutically acceptable carrier.           3. Field of Application Medicine.
PURPOSE:To obtain an oily solid material, remarkably improved in strengths, stability such as oil separation resistance and dispersibility of pigments and useful as an oily base of a cosmetic, a medicine, a crayon, etc., by adding a specific modified polyethylene wax to a liquid oil and/or a solid oil. CONSTITUTION:This oily solid material is obtained by adding a modified polyethylene wax expressed by formula I, II or III [R&lt;1&gt; is a 1-7C saturated hydrocarbon; (n) and (m) are each a number providing an average value of 10-1000; (x) is 0.9-1; R&lt;2&gt; and R&lt;3&gt; are each H, a 1-18C aliphatic hydrocarbon or an aromatic hydrocarbon, with the proviso that R&lt;2&gt; and R&lt;3&gt; are not simultaneously H] to a liquid oil and/or a solid oil. The compound expressed by formula I is prepared by carrying out the living polymerization of, e.g. ethylene and then performing the oxidation with oxygen or reacting formaldehyde and further carrying out the neutralizing treatment with an acid. The compound expressed by formula II is obtained by carrying out the living polymerization of, e.g. ethylene, reacting a carbonyl compound expressed by formula IV therewith and further performing the neutralizing treatment with the acid. The compound expressed by formula III is prepared by carrying out the living polymerization of, e.g. ethylene, reacting a formic acid ester therewith and further performing the neutralizing treatment with the acid.
PROBLEM TO BE SOLVED: To obtain the subject tea leaves desirable in a society with a high percentage of aged people, more effectively and safely drinkable without adverse effects, by making the tea leaves include catechins in a high weight ratio. SOLUTION: These tea leaves contains catechins in &gt;=15 wt.% weight ratio. The teat leaves are preferably cultivated under conditions of a temp. of 25-30 deg.C, 70-90% humidity, and 8,000-12,000 lux illuminance. Only drinking of a small amount of 2.5-5 g of the tea leaves corresponds to a catechin amount by drinking of ordinary tea leaves and eliminates tea drinking in a large amount frequently. The dosage form of the tea leaves to be supplied may be an ordinary teat agent form or powder. The administration of the tea leaves will not impair a taste by a high catechin content.
The present invention relates to methods and pharmaceutical compositions for treating cancer in a subject in need thereof. The inventors believe that the low activity of Serine Hydroxymethyltransferase (SHMT) is due to poor availability of pyridoxal 5&#39; -phosphate (PLP) in cancer cellsWill result in exposure to 5-fluorouracil (FUra) and exposure to N5-formyltetrahydropteroylglutamic acid (5-HCO-H) 4 PteGlu; folinic acid) insufficient growth inhibition in cancer cells of FUra in combination. Cancer cell lines grown in vitro were exposed to FUra as a single dose, and folinic acid-containing FUra in combination with high PLP concentrations. The inventors demonstrated a synergistic and additive interaction of folinic acid and PLP combinations on FUra cytotoxicity in HT29, HCT116 and L1210 cancer cells. Murine studies with high doses of pyridoxamine or pyridoxine showed that intracellular PLP levels were elevated to near or above the Kd levels reported for cofactor binding to SHMT, suggesting that modulation of fluoropyrimidine by vitamin B6 may be achieved in vivo. Accordingly, the present invention relates to an anti-tumor pharmaceutical combination comprising (i) fluoropyrimidine, (ii) B6 isovitamin, and optionally (iii) folic acid, and the use of said combination for the treatment of cancer in a subject in need thereof.
PROBLEM TO BE SOLVED: To obtain a stable and clear fat emulsion preservable for a long period of time even at room temperature, by emulsifying oils and fats in water in the presence of an emulsifying agent and specifying the average particle diameter of fat particles. SOLUTION: This fat emulsion is obtained by emulsifying (A) oils and fats which are preferably vegetable oils such as soybean oil, corn oil, coconut oil, safflower oil and perilla oil in (B) water in the presence of (C) 0.15-3.00 pts.wt. based on 1 pt.wt. of the component A of an emulsifying agent (e.g. purified yolk lecithin) and has 0.003-0.10 μm average particle diameter of fat particles and preferably &lt;200 turbidity. The fat emulsion is obtained, for example, by dispersing the component A and the component B into the component C, coarsely emulsifying the dispersion by using a highpressure jet type homogenizer and finely emulsifying the emulsion by the high-pressure jet type homogenizer at least under 2,000 kgf/cm&lt;2&gt; . Preferably the fat emulsion is mixed with glycerol as a clearing agent.
NEW MATERIAL:A compound shown by the formula I (R1 and R2 are H, or methyl; R3 is H, OH, or methoxy; A is amino acid residue, or dipeptide residue; n is 1, or 2; amino group or functional groups in A may be protected) and its acid addition salt. EXAMPLE:2&#39;&#39;-N-L-Lysyl-5-de-O-methyl-KA-6606 I . USE:An antibiotic, or an intermediate for preparing other antibitoics. PREPARATION:A compound shown by the formula III (e.g., 4-N-glycyl-KA-6606 II, etc.) is reacted with a compound shown by the formula HO-A-H, a compound having a protected functional group except one carboxyl group, or a reactive derivative of one carboxyl group. The protecting group is optionally eliminated, and, if necessary, the reaction product is converted into an acid addition salt.
Earthquake is the type of natural hazard with the highest mortality in the world and in Turkey. The majority of Turkey\&#39;s population lives under the threat of earthquakes.It is necessary to adopt a risk management approach against earthquake danger and to raise conscious individuals.Thanks to earthquake education activities for students, earthquake awareness can be spread to students\&#39; peers, families and teachers. In this way, the society can be resistant to the earthquake hazard.It is recommended that a combination of visual, audio and interactive tools be preferred and technology be used in earthquake education activities.In earthquake education activities, the use of mobile learning method has advantages such as eliminating time and space limitations, increasing equality of opportunity in education, supporting individualized learning and providing instant feedback.

This project will be carried out to examine the effect of the mobile earthquake education application developed for high school students on the students\&#39; level of knowledge about earthquakes. The research will be conducted in two different schools in Konya in the 2023-2024 academic year.The population of the research is 9th grade students in both schools. The sample size was calculated with the Open epi and t was decided to 160 students, 80 experimental and 80 control. In order to prevent interaction between students, one of the schools involved in the research will be the experimental group and the other will be the control group. Groups will be determined with the lottery method.Three 9th grade students from each school will be included in the research. Three classes to be taken into groups in schools will be selected by simple random sampling method. The researcher will collect the pre-tests to all students who meet the research criteria and agree to participate in the study. The researcher will present 2 hours of basic earthquake education to both the experimental and control groups. The students in the experimental group will be registered on the mobile earthquake education. The students in the experimental group will use "mobile earthquake education" for 4 weeks. After 4 weeks, a posttest will be administered to all students in the experimental and control groups. To evaluate the permanence of the mobile earthquake education initiative, a post-test will be administered to participants 8 weeks after the application begins. As data collection form, sociodemographic characteristics survey form, earthquake risk perception scale, earthquake knowledge level survey will be used. The results will be presented with frequency distributions and mean±standard deviation. In the analysis, t test or Mann Whitney U Analysis will be used in independent groups and Variance Analysis or Friedman Analysis of Variance will be used in dependent groups.
FIELD: medicine.SUBSTANCE: group of inventions relates to medicine, specifically to a system and method of clinical support for transferring a patient between care areas using a computer. System comprises a computer-readable storage medium, which contains instructions for performing a method for facilitating patient transfer between care areas using a computer. Method comprises steps of: obtaining current data on a patient currently receiving care in a care area, wherein the current patient data contain data relating to the patient as applied to the current time period. Patient&#39;s medical history data are retrieved, the patient&#39;s medical history data containing data relating to the patient for one or more time periods prior to the current time period. Scores for the transfer of a specific patient from said current data obtained or the patient&#39;s medical history data are calculated, wherein transfer scores of a specific patient are used to form a recommendation for transferring that patient from the current care level to another care level or leaving at the current care level. Weights are calculated for transfer scores of a specific patient, manually or based on the accuracy of previous transfer scores for that patient and the accuracy of previous transfer scores for other patients, and the calculation of the total transfer scores. Weighted combination of said total transfer scores and said transfer scores for the specific patient is calculated to obtain the final transfer scores. System also includes means for obtaining current data about a patient receiving care in the current care area, wherein the current patient data contain data relating to the patient for the current time period. Means for obtaining patient’s medical history data, wherein the patient&#39;s medical history data contain data relating to the patient for one or more time periods prior to the current time period. Means for calculating the scores of a particular patient&#39;s transfer based on the current data obtained and the patient&#39;s medical history data, wherein the transfer scores of the specific patient used to formulate a recommendation for transferring that patient from the current care level to another care level or leaving at the current care level. Means for determining weights for transfer scores of a specific patient manually or based on the accuracy of previous transfer scores for that patient and the accuracy of previous scores for other patients and the calculation of the total transfer scores. And means for calculating a weighted combination of said total transfer scores and said transfer scores for the specific patient to obtain the final transfer scores.EFFECT: group of inventions allows for effective planning by the practitioner of resources and the appointment of patient care.14 cl, 6 dwg
The present invention relates to liver medicinal powder which belongs to a traditional Chinese medicine product of a medicine of people&#39;s living class. The present invention is a Chinese medicine for curing hepatic diseases, the curative effect is enhanced, and the treatment cycle is shortened. The prescription comprises dendrobe, trumpetcreeper flower, corydalis tuber, bezoar, honeysuckle flower, schisandra, viola herb, etc. A fresh hen liver, a cony liver and a hen are used as extra conductant ingredients. The present invention has the preparing method that the hen is slaughtered, five viscera are removed, the medicines are pulverized, uniformly mixed, and are put in the hen together with the hen liver and the cony liver for steaming for 10 hours, and the traditional Chinese medicines are taken out and dried and made into powder. The power is divided into 15 parts, and people take one part every day. The optimal taking time is 22-0 o&#39;clock at night, and 15 days is a course of treatment.
The invention provides an isolated polypeptide including an immunoglobulin CH3 region domain polypeptide, or functional fragment thereof, having at least one Pro to GIy substitution and exhibiting enhanced stability, including an enhanced folding rate, compared to an unsubstituted CH3 domain, wherein the at least one Pro to GIy substitution comprises CH3 residue Pro38 or a CH3 domain equivalent thereof. Multimeric complexes of an immunoglobulin CH3 region domain polypeptide, or functional fragment thereof, having at least one Pro to GIy substitution with a second immunoglobulin CH3 region domain polypeptide also are provided by the invention. The multimeric complexes can include antibodies, antibody functional fragments such as Fd, Fv, Fab, F(ab&#39;), F(ab)2, F(ab&#39;)2, single chain Fv (scFv), chimeric antibodies, diabodies, triabodies, tetrabodies or minibody and other binding polypeptides having an immunoglobulin CH3 region domain polypeptide such as a peptibody or an Fc fusion polypeptide. An isolated population of polypeptides including a plurality of immunoglobulin CH3 region domain polypeptides, or functional fragments thereof, is further provided. Each CH3 region domain polypeptide within the populations includes at least one Pro to GIy substitution and exhibits enhanced stability, including an enhanced folding rate, compared to an unsubstituted CH3 domain, wherein the at least one Pro to GIy substitution comprises CH3 residue Pro38 or a CH3 domain equivalent thereof. The invention further provides a method of producing a multimeric binding polypeptide and a method of treating a pathological condition characterized by aberrant cell growth.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a polysaccharide fine particle capable of being inexpensively and easily manufactured and further arbitrarily controlling a particle diameter of nano size order, i.e., a particle diameter less than 1 μm, and its manufacturing method.  &lt;P&gt;SOLUTION: A polysaccharide solution in which polysaccharide is dissolved in an acid solvent is added to an aqueous solution containing at least one kind selected from the group consisting of a magnesium salt, an iron salt, a copper salt and a zinc salt of a divalent or more of anion as a dispersion medium which is made 100 pts.vol. or more relative to 100 pts.vol. of the polysaccharide solution or an aqueous solution containing at least one kind of a metal salt of a divalent or more of anion and a metal salt of a chloride ion. Thereafter, the polysaccharide is associated/precipitated by removing the at least excessive hydrogen ion from a mixture solution of the polysaccharide solution and the dispersion medium. Thereby, the particle diameter can be controlled to an arbitral numerical value less than 1 μm.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT